Eiger announces expanded license agreement with Merck and collaboration with The PRF
Eiger announced it has expanded its licensing agreement with Merck to include rights to develop the investigational farnesyltransferase inhibitor lonafarnib for treatment of HGPS or Progeria. Concurrently, Eiger announced it has completed a collaboration agreement with The PRF. May 16, 2018